vs
Side-by-side financial comparison of Amarin Corp plc (AMRN) and Cheche Group Inc. (CCG). Click either name above to swap in a different company.
Amarin Corp plc is the larger business by last-quarter revenue ($45.1M vs $32.8M, roughly 1.4× Cheche Group Inc.). Cheche Group Inc. runs the higher net margin — 0.5% vs -23.3%, a 23.8% gap on every dollar of revenue.
Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.
Cheche Group Inc. is a leading automotive digital service provider headquartered in China. It offers integrated solutions including auto insurance intermediary services, smart auto after-sales support, and connected vehicle technology products, serving individual car owners, auto dealerships, and insurance partners across domestic and select Southeast Asian markets.
AMRN vs CCG — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $45.1M | $32.8M |
| Net Profit | $-10.5M | $153.6K |
| Gross Margin | — | 5.7% |
| Operating Margin | 35.5% | — |
| Net Margin | -23.3% | 0.5% |
| Revenue YoY | 7.0% | — |
| Net Profit YoY | 33.0% | — |
| EPS (diluted) | — | $0.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $45.1M | $32.8M | ||
| Q4 25 | $49.2M | — | ||
| Q3 25 | $49.7M | — | ||
| Q2 25 | $72.7M | $26.0M | ||
| Q1 25 | $42.0M | — | ||
| Q4 24 | $62.3M | $18.6M | ||
| Q3 24 | $42.3M | — | ||
| Q2 24 | $67.5M | $36.1M |
| Q1 26 | $-10.5M | $153.6K | ||
| Q4 25 | $-1.2M | — | ||
| Q3 25 | $-7.7M | — | ||
| Q2 25 | $-14.1M | $-492.4K | ||
| Q1 25 | $-15.7M | — | ||
| Q4 24 | $-48.6M | $-196.7K | ||
| Q3 24 | $-25.1M | — | ||
| Q2 24 | $1.5M | $-7.6M |
| Q1 26 | — | 5.7% | ||
| Q4 25 | 47.1% | — | ||
| Q3 25 | 44.7% | — | ||
| Q2 25 | 69.2% | 4.9% | ||
| Q1 25 | 59.8% | — | ||
| Q4 24 | -15.4% | 5.2% | ||
| Q3 24 | 38.5% | — | ||
| Q2 24 | 63.4% | 4.3% |
| Q1 26 | 35.5% | — | ||
| Q4 25 | -12.9% | — | ||
| Q3 25 | -22.4% | — | ||
| Q2 25 | -22.0% | -2.0% | ||
| Q1 25 | -39.9% | — | ||
| Q4 24 | -84.3% | -0.3% | ||
| Q3 24 | -59.5% | — | ||
| Q2 24 | -0.8% | -4.7% |
| Q1 26 | -23.3% | 0.5% | ||
| Q4 25 | -2.5% | — | ||
| Q3 25 | -15.6% | — | ||
| Q2 25 | -19.4% | -1.9% | ||
| Q1 25 | -37.4% | — | ||
| Q4 24 | -78.0% | -1.1% | ||
| Q3 24 | -59.4% | — | ||
| Q2 24 | 2.3% | -21.0% |
| Q1 26 | — | $0.00 | ||
| Q4 25 | $0.00 | — | ||
| Q3 25 | $-0.02 | — | ||
| Q2 25 | $-0.03 | $-0.01 | ||
| Q1 25 | $-0.04 | — | ||
| Q4 24 | $-0.12 | $-0.00 | ||
| Q3 24 | $-0.06 | — | ||
| Q2 24 | $0.00 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $307.8M | $20.0M |
| Total DebtLower is stronger | — | $193.3K |
| Stockholders' EquityBook value | — | — |
| Total Assets | $645.8M | $203.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $307.8M | $20.0M | ||
| Q4 25 | $302.6M | — | ||
| Q3 25 | $286.6M | — | ||
| Q2 25 | $298.7M | $23.1M | ||
| Q1 25 | $281.8M | — | ||
| Q4 24 | $294.2M | $21.1M | ||
| Q3 24 | $305.7M | — | ||
| Q2 24 | $306.7M | $28.2M |
| Q1 26 | — | $193.3K | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $690.0K | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | $459.3M | — | ||
| Q3 25 | $458.9M | — | ||
| Q2 25 | $464.9M | $47.1M | ||
| Q1 25 | $473.7M | — | ||
| Q4 24 | $486.2M | $49.1M | ||
| Q3 24 | $531.4M | — | ||
| Q2 24 | $551.9M | $48.6M |
| Q1 26 | $645.8M | $203.5M | ||
| Q4 25 | $670.8M | — | ||
| Q3 25 | $659.8M | — | ||
| Q2 25 | $670.1M | $177.3M | ||
| Q1 25 | $655.7M | — | ||
| Q4 24 | $685.3M | $177.7M | ||
| Q3 24 | $750.6M | — | ||
| Q2 24 | $799.9M | $139.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.01× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMRN
| U.S | $35.6M | 79% |
| Europe | $4.9M | 11% |
| Rest-of-World (ROW) | $2.8M | 6% |
| Licensing & Royalties | $1.8M | 4% |
CCG
Segment breakdown not available.
